BioCryst Pharmaceuticals | BCRX - Ebitda


BioCryst Pharmaceuticals reported $51.7M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Chugai Pharma JPY 158.77B 10.24B Mar/2026
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
DBV Technologies USD -33.48M 5.55M Sep/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Incyte USD 367.97M 46.53M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novavax USD 19.36M 190.79M Dec/2025
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026